2Department of Urology, Istanbul Medeniyet University, Istanbul-Turkey
3Department of Public Health, Istanbul Medeniyet University, Istanbul-Turkey DOI : 10.5505/tjo.2021.2830 OBJECTIVE Prostate cancer is one of the most common cancers in male gender. Despite recent advances in the diagnosis and the treatment methods, more reliable molecular biomarkers have been needed for the diagnosis and evaluation of response to treatments such as chemotherapy, anti-androgen therapy, and radiotherapy. The aim of this study is to investigate promoter methylation status of HOX3D and PCDH17 genes in prostate cancer in Turkish population.
METHODS
A total of 46 patients with prostate cancer were included in this study. Tissue samples obtained from
36 patients with benign prostate hyperplasia were used as controls. Methylation status of HOXD3 and
PCDH17 genes was determined by quantitative Methylation-Specific PCR with commercially available
primer sets.
RESULTS
Both HOXD3 and PCDH17 promoter methylation was determined significantly higher in patients
with compare to controls (p=0.0198 and p=0.0386, respectively). A significant but weak correlation
was found between methylation status and pre-operative PSA level for HOXD3 (Spearman"s rho=0.259,
p=0.02) and PCDH17 gene (Spearman"s rho=0.324, p=0.006).
CONCLUSION
Our results indicated that HOXD3 and PCDH17 promoter methylation levels are higher in patients with
prostate cancer. Further studies with large sample cohorts and clinicopathological data will enlighten
presumptive role of HOXD3 and PCDH17 methylation status.